{
    "ticker": "LEXXW",
    "name": "Lexaria Bioscience Corp.",
    "description": "Lexaria Bioscience Corp. is a biotechnology company focused on the development and commercialization of its proprietary drug delivery technology, DehydraTECH\u2122, which enhances the bioavailability and absorption of active pharmaceutical ingredients (APIs). Founded in 2004, Lexaria aims to revolutionize the way drugs, including cannabinoids, are delivered and absorbed by the human body. The company primarily targets the health and wellness sector, including applications in pain management, cardiovascular health, nicotine delivery, and various other therapeutic areas. Lexaria's innovative technology has the potential to improve the effectiveness of existing drugs and reduce the side effects often associated with traditional delivery methods. By leveraging DehydraTECH\u2122, Lexaria is working to develop a range of products that can be used in both prescription medications and consumer goods. The company's ongoing research and development efforts are aimed at expanding its product pipeline and securing partnerships with industry leaders to bring its technology to market. With a strong commitment to scientific rigor and regulatory compliance, Lexaria is well-positioned to make significant contributions to the pharmaceutical and nutraceutical industries.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Kelowna, British Columbia, Canada",
    "founded": "2004",
    "website": "https://www.lexariabioscience.com",
    "ceo": "Chris Bunka",
    "social_media": {
        "twitter": "https://twitter.com/LexariaBiosci",
        "linkedin": "https://www.linkedin.com/company/lexaria-bioscience-corp/"
    },
    "investor_relations": "https://www.lexariabioscience.com/investors/",
    "key_executives": [
        {
            "name": "Chris Bunka",
            "position": "CEO"
        },
        {
            "name": "Cynthia Decker",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceuticals",
            "products": [
                "DehydraTECH-processed cannabinoids",
                "DehydraTECH-processed nicotine"
            ]
        },
        {
            "category": "Nutraceuticals",
            "products": [
                "CBD-infused products",
                "Health supplements"
            ]
        }
    ],
    "seo": {
        "meta_title": "Lexaria Bioscience Corp. | Advanced Drug Delivery Solutions",
        "meta_description": "Explore Lexaria Bioscience Corp., a leader in drug delivery technology, enhancing the bioavailability of cannabinoids and other APIs through its patented DehydraTECH\u2122 technology.",
        "keywords": [
            "Lexaria",
            "Drug Delivery",
            "Cannabinoids",
            "Biotechnology",
            "DehydraTECH",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Lexaria known for?",
            "answer": "Lexaria is known for its proprietary DehydraTECH\u2122 technology that enhances the bioavailability of cannabinoids and other active ingredients."
        },
        {
            "question": "Who is the CEO of Lexaria?",
            "answer": "Chris Bunka is the CEO of Lexaria Bioscience Corp."
        },
        {
            "question": "Where is Lexaria headquartered?",
            "answer": "Lexaria is headquartered in Kelowna, British Columbia, Canada."
        },
        {
            "question": "What are Lexaria's main products?",
            "answer": "Lexaria's main products include DehydraTECH-processed cannabinoids and nicotine, as well as various health supplements."
        },
        {
            "question": "When was Lexaria founded?",
            "answer": "Lexaria was founded in 2004."
        }
    ],
    "competitors": [
        "GWPH",
        "CRON",
        "APHA"
    ],
    "related_stocks": [
        "AAPL",
        "AMZN",
        "MSFT",
        "GOOGL"
    ]
}